Clinical Controversies in the Management of Metastatic Colorectal Cancer

Select Publications

HOCHSTER


**ZALCBERG**


**VAN CUTSEMG**


Sobrero AF et al. Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2012;Abstract 387.

Tabernero J et al. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. European Multidisciplinary Congress 2011;Abstract 6LBA.


**ARNOLD**


Griebsch I et al. The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study. Proc ASCO 2011;Abstract 3626.

Grothey A et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal Cancers Symposium 2012;Abstract LBA385.


Siena S et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Gastrointestinal Cancers Symposium 2012;Abstract 283.

Tabernero J et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). Proc ASCO 2010;Abstract 3501.

VENOOK


McCahill LE et al. A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. Proc ASCO 2010;Abstract 3527.